GTx Inc (GTXI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GTx Inc (GTXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9894
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GTx Inc (GTx) is a biopharmaceutical company that discovers, develops and commercializes novel targeted hormonal therapies. It develops small molecules that targets hormone pathways for the treatment of various cancers including breast and prostate cancer; and other serious medical conditions. The company is further focused on developing selective androgen receptor modulators (SARMs), a class of drugs that have the potential to be used as a hormonal therapy for treating advanced breast cancer and other serious medical conditions, such as stress urinary incontinence (SUI) and Duchenne muscular dystrophy (DMD). GTx is developing enobosarm, a SARM in Phase II trials for treating breast cancer and stress urinary incontinence. GTx is headquartered in Memphis, Tennessee, the US.

GTx Inc (GTXI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GTx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GTx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GTx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GTx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GTx Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
GTx Raises USD48.5 Million in Venture Financing 10
Licensing Agreements 11
GTx Enters into Licensing Agreement with University of Tennessee Research Foundation 11
Equity Offering 13
GTx to Raise up to USD50 Million in Public Offering of Shares 13
GTx Plans to Raise Funds through Public Offering of Shares 14
GTx Raises USD48.5 Million in Private Placement of Shares 15
Gtx to Raise USD14 Million in Private Placement of Shares 17
Gtx Raises USD43 Million in Private Placement of Shares and Warrants 18
GTx Completes Private Placement Of Units For US$21.3 Million 20
Asset Transactions 21
ProStrakan Acquires Breast Cancer Product Fareston From GTx For US$22 Million 21
GTx Inc – Key Competitors 22
GTx Inc – Key Employees 23
GTx Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: GTx provides corporate update and reports second quarter 2018 financial results 25
May 15, 2018: GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results 26
Mar 12, 2018: GTx Reports Fourth Quarter and Full Year 2017 Financial Results 28
Nov 14, 2017: GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results 30
Aug 14, 2017: GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results 32
May 15, 2017: GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results 34
Mar 15, 2017: GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
GTx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GTx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GTx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GTx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
GTx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GTx Raises USD48.5 Million in Venture Financing 10
GTx Enters into Licensing Agreement with University of Tennessee Research Foundation 11
GTx to Raise up to USD50 Million in Public Offering of Shares 13
GTx Plans to Raise Funds through Public Offering of Shares 14
GTx Raises USD48.5 Million in Private Placement of Shares 15
Gtx to Raise USD14 Million in Private Placement of Shares 17
Gtx Raises USD43 Million in Private Placement of Shares and Warrants 18
GTx Completes Private Placement Of Units For US$21.3 Million 20
ProStrakan Acquires Breast Cancer Product Fareston From GTx For US$22 Million 21
GTx Inc, Key Competitors 22
GTx Inc, Key Employees 23

List of Figures
GTx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GTx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
GTx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GTx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[GTx Inc (GTXI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nuvelution Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Nuvelution Pharma Inc (Nuvelution Pharma) is a developer of late-stage clinical assets. The company offers research and development risk-sharing approach to pharmaceutical and biotechnology companies. It facilitates advancement of late-stage clinical assets where research and development bud …
  • International Coffee & Tea, LLC:企業の戦略・SWOT・財務情報
    International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report Summary International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Arris International Plc:企業のM&A・事業提携・投資動向
    Arris International Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Arris International Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Vistin Pharma AS (VISTIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies active pharmaceutical ingredients and solid dosage forms. The company’s products include opioids, an analgesics and antitussive; metformin, an API for the treatment of diabetes II; …
  • New York Power Authority:企業の戦略・SWOT・財務分析
    New York Power Authority - Strategy, SWOT and Corporate Finance Report Summary New York Power Authority - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Alimera Sciences Inc (ALIM):医療機器:M&Aディール及び事業提携情報
    Summary Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabet …
  • Guizhou Space Appliance Co., Ltd.:企業の戦略・SWOT・財務分析
    Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Niko Resources Ltd (NKO):石油・ガス:M&Aディール及び事業提携情報
    Summary Niko Resources Ltd (Niko Resources) is an independent oil and gas exploration and production company that acquires, explores, develops and produces crude oil and natural gas properties. The company concentrates on value generation in the D6 Block in India. It offers financing options for the …
  • Tecomet Inc:医療機器:M&Aディール及び事業提携情報
    Summary Tecomet Inc (Tecomet) is a medical equipment company that manufactures and markets cases, implants and instruments. The company offers various implants which include acetabular cups, femoral heads, femoral stems, poly liners, femoral wraps, patellas, poly inserts, tibia trays, hooks, plates, …
  • ViaCyte Inc-製薬・医療分野:企業M&A・提携分析
    Summary ViaCyte Inc (ViaCyte), formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline product portfolio includes VC-01, which is being developed as a therapy for T1D patients who h …
  • Ortho-Clinical Diagnostics Inc:企業のM&A・事業提携・投資動向
    Ortho-Clinical Diagnostics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ortho-Clinical Diagnostics Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • US Physical Therapy Inc (USPH):製薬・医療:M&Aディール及び事業提携情報
    Summary US Physical Therapy Inc (USPh) operates outpatient physical and occupational therapy clinics that offer pre-and post-operative care. The company provides treatment for orthopedic-related disorders, preventative care, sports-related injuries, rehabilitation of injured workers and neurological …
  • Schouw & Co. A/S:戦略・SWOT・企業財務分析
    Schouw & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary Schouw & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Volex plc (VLX):企業の財務・戦略的SWOT分析
    Volex plc (VLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Bio2 Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bio2 Medical Inc (Bio2 Medical) is a medical device company that develops vascular devices. The company’s products include angel catheter, an inferior vena cava filter for pulmonary embolism protection and access to the central venous system in critically ill patients. Its device is designed …
  • China Construction Bank Corp:企業の戦略・SWOT・財務分析
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Dignity plc (DTY):企業の財務・戦略的SWOT分析
    Dignity plc (DTY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bank Sohar SAOG (BKSB):企業の財務・戦略的SWOT分析
    Bank Sohar SAOG (BKSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Care UK Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Care UK Ltd (Care UK) is a healthcare service provider that offers clinical and social care services. The company’s healthcare services include treatment centres, General Practitioner(GP) practices, NHS walk-in centres, GP out-of-hours, prison health services, clinical assessment, diagnostic …
  • MedImmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆